These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 31389381)
1. Evaluatıon of hypofractıonated stereotactıc radıotherapy (HFSRT) to the resectıon cavıty after surgıcal resectıon of braın metastases: A sıngle center experıence. Dincoglan F; Sager O; Uysal B; Demiral S; Gamsiz H; Gündem E; Elcim Y; Dirican B; Beyzadeoglu M Indian J Cancer; 2019; 56(3):202-206. PubMed ID: 31389381 [TBL] [Abstract][Full Text] [Related]
2. HFSRT of the resection cavity in patients with brain metastases. Specht HM; Kessel KA; Oechsner M; Meyer B; Zimmer C; Combs SE Strahlenther Onkol; 2016 Jun; 192(6):368-76. PubMed ID: 26964777 [TBL] [Abstract][Full Text] [Related]
3. Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Bilger A; Bretzinger E; Fennell J; Nieder C; Lorenz H; Oehlke O; Grosu AL; Specht HM; Combs SE Cancer Med; 2018 Jun; 7(6):2350-2359. PubMed ID: 29745035 [TBL] [Abstract][Full Text] [Related]
4. Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial. Waltenberger M; Bernhardt D; Diehl C; Gempt J; Meyer B; Straube C; Wiestler B; Wilkens JJ; Zimmer C; Combs SE BMC Cancer; 2023 Jul; 23(1):709. PubMed ID: 37516835 [TBL] [Abstract][Full Text] [Related]
5. Evidence of dose-response following hypofractionated stereotactic radiotherapy to the cavity after surgery for brain metastases. Garimall S; Shanker M; Johns E; Watkins T; Olson S; Huo M; Foote MC; Pinkham MB J Neurooncol; 2020 Jan; 146(2):357-362. PubMed ID: 31907796 [TBL] [Abstract][Full Text] [Related]
6. Hypofractionated stereotactic radiotherapy (hfSRT) after tumour resection of a single brain metastasis: report of a single-centre individualized treatment approach. Steinmann D; Maertens B; Janssen S; Werner M; Frühauf J; Nakamura M; Christiansen H; Bremer M J Cancer Res Clin Oncol; 2012 Sep; 138(9):1523-9. PubMed ID: 22526164 [TBL] [Abstract][Full Text] [Related]
7. Risk of radiation necrosis after hypofractionated stereotactic radiotherapy (HFSRT) for brain metastases: a single center retrospective study. Di Perri D; Tanguy R; Malet C; Robert A; Sunyach MP J Neurooncol; 2020 Sep; 149(3):447-453. PubMed ID: 32979130 [TBL] [Abstract][Full Text] [Related]
8. Hypofractionated Stereotactic Radiation Therapy to the Resection Bed for Intracranial Metastases. Keller A; Doré M; Cebula H; Thillays F; Proust F; Darié I; Martin SA; Delpon G; Lefebvre F; Noël G; Antoni D Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1179-1189. PubMed ID: 28974415 [TBL] [Abstract][Full Text] [Related]
9. Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Bachmann N; Leiser D; Ermis E; Vulcu S; Schucht P; Raabe A; Aebersold DM; Herrmann E Radiat Oncol; 2019 Mar; 14(1):45. PubMed ID: 30871597 [TBL] [Abstract][Full Text] [Related]
10. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer). Lesueur P; Lequesne J; Barraux V; Kao W; Geffrelot J; Grellard JM; Habrand JL; Emery E; Marie B; Thariat J; Stefan D Radiat Oncol; 2018 Jul; 13(1):138. PubMed ID: 30055640 [TBL] [Abstract][Full Text] [Related]
11. Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation. Mengue L; Bertaut A; Ngo Mbus L; Doré M; Ayadi M; Clément-Colmou K; Claude L; Carrie C; Laude C; Tanguy R; Blanc J; Sunyach MP Radiat Oncol; 2020 Apr; 15(1):82. PubMed ID: 32303236 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis. Keller A; Lefebvre F; Ricard D; Noël G; Antoni D Chin Clin Oncol; 2020 Aug; 9(4):55. PubMed ID: 32576020 [TBL] [Abstract][Full Text] [Related]
13. Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy. Croker J; Chua B; Bernard A; Allon M; Foote M Clin Exp Metastasis; 2016 Feb; 33(2):125-32. PubMed ID: 26482476 [TBL] [Abstract][Full Text] [Related]
14. Single-fraction radiosurgery versus fractionated stereotactic radiotherapy in patients with brain metastases: a comparative study. Loo M; Pin Y; Thierry A; Clavier JB Clin Exp Metastasis; 2020 Jun; 37(3):425-434. PubMed ID: 32185576 [TBL] [Abstract][Full Text] [Related]
15. Cavity volume changes after surgery of a brain metastasis-consequences for stereotactic radiation therapy. Scharl S; Kirstein A; Kessel KA; Duma MN; Oechsner M; Straube C; Combs SE Strahlenther Onkol; 2019 Mar; 195(3):207-217. PubMed ID: 30386864 [TBL] [Abstract][Full Text] [Related]
16. Hypofractionated stereotactic radiotherapy of limited brain metastases: a single-centre individualized treatment approach. Märtens B; Janssen S; Werner M; Frühauf J; Christiansen H; Bremer M; Steinmann D BMC Cancer; 2012 Oct; 12():497. PubMed ID: 23098039 [TBL] [Abstract][Full Text] [Related]
17. Cyberknife Telentschak S; Ruess D; Grau S; Goldbrunner R; von Spreckelsen N; Jablonska K; Treuer H; Kocher M; Ruge M J Cancer Res Clin Oncol; 2021 Sep; 147(9):2765-2773. PubMed ID: 33638006 [TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940 [TBL] [Abstract][Full Text] [Related]
19. Brain metastases treated with radiosurgery or hypofractionated stereotactic radiotherapy: outcomes and predictors of survival. Sallabanda M; García-Berrocal MI; Romero J; García-Jarabo V; Expósito MJ; Rincón DF; Zapata I; Magallón MR Clin Transl Oncol; 2020 Oct; 22(10):1809-1817. PubMed ID: 32124243 [TBL] [Abstract][Full Text] [Related]